chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute kidney injury, Cardiac failure congestive, Chronic obstructive pulmonary disease, Condition aggravated, Dialysis
Clinical narrative: Narrative: Patient is 70 y/o M with PMH of schizophrenia, hypertriglyceridemia, PAD, iron deficiency anemia, CKD stage 4, insomnia, folic acid deficiency, BPH, HLD, CHF, COPD, glaucoma, B-cell lymphoma, neurogenic bladder, Hep C, Diabetes insipidus, HTN, GERD, DM that was transferred from his nursing home residence to the acute care hospital for suspected aspiration pneumonia failing outpatient treatment. Patient had recent admission to an outside hospital for COPD/CHF exacerbation and UTI. COVID-19 test was negative 4/15/21, the date of his admission. During course of admission, patient respiratory status worsened requiring intubation, mechanical ventilation, and supportive critical care. He developed AKI requiring dialysis and had progression of CHF with EF of 15%. Patient did not have repeat COVID-19 test during his admission. Repeat COVID-19 test at time of discharged on 5/19/21 was negative. However, because of clinical deterioration including multi-system inflammatory syndrome and organ failure with poor response to antibiotic therapy, provider feels that the patient may have had COVID-19 which was clinically diagnosed but not identified on initial COVID-19 test. Provider obtained COVID-19 antibodies obtained at LTAC facility and found to positive without other know COVID-19 infection.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Disease progression, Ejection fraction decreased, Endotracheal intubation, General physical health deterioration, Mechanical ventilation
Clinical narrative: Narrative: Patient is 70 y/o M with PMH of schizophrenia, hypertriglyceridemia, PAD, iron deficiency anemia, CKD stage 4, insomnia, folic acid deficiency, BPH, HLD, CHF, COPD, glaucoma, B-cell lymphoma, neurogenic bladder, Hep C, Diabetes insipidus, HTN, GERD, DM that was transferred from his nursing home residence to the acute care hospital for suspected aspiration pneumonia failing outpatient treatment. Patient had recent admission to an outside hospital for COPD/CHF exacerbation and UTI. COVID-19 test was negative 4/15/21, the date of his admission. During course of admission, patient respiratory status worsened requiring intubation, mechanical ventilation, and supportive critical care. He developed AKI requiring dialysis and had progression of CHF with EF of 15%. Patient did not have repeat COVID-19 test during his admission. Repeat COVID-19 test at time of discharged on 5/19/21 was negative. However, because of clinical deterioration including multi-system inflammatory syndrome and organ failure with poor response to antibiotic therapy, provider feels that the patient may have had COVID-19 which was clinically diagnosed but not identified on initial COVID-19 test. Provider obtained COVID-19 antibodies obtained at LTAC facility and found to positive without other know COVID-19 infection.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Multisystem inflammatory syndrome, Organ failure, Pneumonia aspiration, Respiratory disorder, SARS-CoV-2 antibody test positive
Clinical narrative: Narrative: Patient is 70 y/o M with PMH of schizophrenia, hypertriglyceridemia, PAD, iron deficiency anemia, CKD stage 4, insomnia, folic acid deficiency, BPH, HLD, CHF, COPD, glaucoma, B-cell lymphoma, neurogenic bladder, Hep C, Diabetes insipidus, HTN, GERD, DM that was transferred from his nursing home residence to the acute care hospital for suspected aspiration pneumonia failing outpatient treatment. Patient had recent admission to an outside hospital for COPD/CHF exacerbation and UTI. COVID-19 test was negative 4/15/21, the date of his admission. During course of admission, patient respiratory status worsened requiring intubation, mechanical ventilation, and supportive critical care. He developed AKI requiring dialysis and had progression of CHF with EF of 15%. Patient did not have repeat COVID-19 test during his admission. Repeat COVID-19 test at time of discharged on 5/19/21 was negative. However, because of clinical deterioration including multi-system inflammatory syndrome and organ failure with poor response to antibiotic therapy, provider feels that the patient may have had COVID-19 which was clinically diagnosed but not identified on initial COVID-19 test. Provider obtained COVID-19 antibodies obtained at LTAC facility and found to positive without other know COVID-19 infection.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test negative, Therapeutic response decreased, Treatment failure, Urinary tract infection
Clinical narrative: Narrative: Patient is 70 y/o M with PMH of schizophrenia, hypertriglyceridemia, PAD, iron deficiency anemia, CKD stage 4, insomnia, folic acid deficiency, BPH, HLD, CHF, COPD, glaucoma, B-cell lymphoma, neurogenic bladder, Hep C, Diabetes insipidus, HTN, GERD, DM that was transferred from his nursing home residence to the acute care hospital for suspected aspiration pneumonia failing outpatient treatment. Patient had recent admission to an outside hospital for COPD/CHF exacerbation and UTI. COVID-19 test was negative 4/15/21, the date of his admission. During course of admission, patient respiratory status worsened requiring intubation, mechanical ventilation, and supportive critical care. He developed AKI requiring dialysis and had progression of CHF with EF of 15%. Patient did not have repeat COVID-19 test during his admission. Repeat COVID-19 test at time of discharged on 5/19/21 was negative. However, because of clinical deterioration including multi-system inflammatory syndrome and organ failure with poor response to antibiotic therapy, provider feels that the patient may have had COVID-19 which was clinically diagnosed but not identified on initial COVID-19 test. Provider obtained COVID-19 antibodies obtained at LTAC facility and found to positive without other know COVID-19 infection.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Arrhythmia, Death, Diabetes mellitus
Clinical narrative: Narrative: Patient received his Moderna COVID vaccine #1 on 4/15/21. No notes or scanned records entered to indicate what happened from that time until 5/7/21 when patient's wife was called due to a missed appt and she reported that he had passed away on 5/2/2021. Time from vaccine to date of death is 17 days. Note in database was entered on 5/17/21 to indicate cause of death as lethal arrhythmia and diabetes mellitus. No autopsy report available.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Fall, Life support, Orthosis user, Unresponsive to stimuli
Clinical narrative: Narrative:  Patient with h/o legally blind, CKD stage 4, Emphysema (recent chest X-ray okay), A-fib,cardiomyopathy, and ICD. He continues to wear a C-collar from a s/p fall on 4/29/21 at medical appointment. Per database note, pt passed away at medical center on 5/14/21. It was noted that he was unresponsive and it was intended that he would be removed from Life Support on this day. It appears this death is unrelated to the covid vaccines previously administered on 2/24/21 & 3/24/21.
Age: 72.0
Sex: M
Vaccine: VARZOS
Symptoms: Product preparation error, Product preparation issue
Clinical narrative: Narrative:  Patient was scheduled for shingrix vaccine. RN preparing the vaccine did not reconstitue the vaccine. She administered diluent only. The patient was notified and advised to reschedule in 4 wks.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Lower respiratory tract congestion, Pyrexia
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for supplemental oxygen, cardiac arrest, diabetes, CAD, chf, hyperlipidemia, htn, dementia. Per note 4/21. patient was experiencing decline after cardiac arrest in March 2020. Was taken to Emergency room on 5/14 with a chief complaint of fever and chest congestion by wife. Deceased noted to be 5/14 however no information available.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for adenocarcinoma of pancreas, sleep apnea, malignant neoplasm of pancreas, aortic stenosis, diabetes, neuropathy, vitamin d deficiency, gout, angina, dyslipidemia, CAD. Pt was under the care of Hospice for end stage pancreatic adenocarcinoma. No information regarding death available.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal distension, Abdominal pain, Aspiration, Azotaemia, B-cell lymphoma
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Colectomy, Computerised tomogram abdomen abnormal, Death, Decreased appetite, Device difficult to use
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Enema administration, Gastrointestinal tube insertion, General physical health deterioration, Hypotension, Hypoxia
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Intensive care, Intra-abdominal fluid collection, Mental status changes, Nausea, Nothing by mouth order
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal suctioning, Respiratory failure, Septic shock, Small intestinal obstruction, Tachycardia
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is a 79 yo who was transferred to the MICU for hypoxemic resp failure due to aspiration, SBO and septic shock. He has history of relapsing CLL, diverticulitis s/p Hartmann's with reversal, diastolic heart failure, A fib/flutter, Type 1 DM HTN, moderate aortic stenosis and adenocarcinoma now s/p adhesiolysis, and partial transverse colectomy in March 2021, recent dx of b cell NHL in the inguinal lymph node. Hepresentedon May 20 2021 for Abd pain. Prior to this admission, he was discharged on 5/17/2021 for SBO, requiring enemas and NG suction. Pt improved transiently, and again had worsening abd pain, distention, poor appetite and nause. Pt's abd CT showed air fluid levels. Pt admitted to the medical service, however, had difficulty placing NG tube. Pt followed by surgery, noted to have BMs, remained NPO. Yesterday, pt patient acutely became hypoxic needing NRB. This was accompanied by tachycardia to 130s and altered mental status. Pt had an episode of emesis, brought to ICU, NG placed with > 1L of gastric fluid removal, had markedly distended abdomen, hyoxic on NRB and HFNC O2. Overnight, pt continued to deteriorate, hypoxic, hypotensive on pressors. He became uremic and continued to deteriorate, through out the night. His daughter attempted to come early this am (3am) but was involved in MVA, transported to hospital. Per his daughter, he was adamant he did not want intubation or heroic measures nor additional surgeries. He was DNR. Due to his comorbidities, we will honor his wishes but continued aggressive measures short of intubation or CPR. Despite fluids, pressors, pt progressively deteriorated and died at 1157am
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Cardio-respiratory arrest, Condition aggravated, Death, Lung cancer metastatic
Clinical narrative: Narrative:  Pt was a 67 YO male with PMH of MDS, lung cancer, CAD, HLD, cardiomyopathy, arrhythmia, barrett's esophagus, HTN, PVD, and HLD in care of inpatient hospice who passed away from cardiopulmonary arrest due to metastatic lung cancer.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 99.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Chest pain, Chills, Diarrhoea, Percutaneous coronary intervention
Clinical narrative: Narrative: Pt received Janssen COVID vaccine on 5/24. Reported fever and chills approx 24 hours after hospitalization which resolved. Reported diarrhea on day 4 for one night and again on day 6 for one night. On day 7, pt began experiencing chest pain while on vacation. He was evaluated in local hospital on 5/31/2021 for STEMI, flown to another hospital on 6/1 for PCI and post MI care. Per chart review, pt had forgotten his medications while on vacation and had not taken his ASA or ticagrelor for 3 days. He has a significant CAD hx and has had 7 stents placed in the past per family report.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Narrative: Pt received Janssen COVID vaccine on 5/24. Reported fever and chills approx 24 hours after hospitalization which resolved. Reported diarrhea on day 4 for one night and again on day 6 for one night. On day 7, pt began experiencing chest pain while on vacation. He was evaluated in local hospital on 5/31/2021 for STEMI, flown to another hospital on 6/1 for PCI and post MI care. Per chart review, pt had forgotten his medications while on vacation and had not taken his ASA or ticagrelor for 3 days. He has a significant CAD hx and has had 7 stents placed in the past per family report.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test negative, Unevaluable event
Clinical narrative: Narrative:
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Cardiac disorder, Death
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient is 81 year old with past medical history of CAD, A.Fib, CHF, Hypertension complicated by retinopathy, type 2 diabetes, obstructive sleep apnea, dyslipidemia, GERD, CVA in early and left carotid arterial stenosis, gout, calculus of kidney, Osteoarthritis of left knee joint, Hematuria, Degeneration of lumbar Intervertebral disc, memory lapses. Recent note said Patient passed away on 5.17 at hospital, heart complications. There were no other specific notes found. Patient received both doses of Pfizer COVID vaccine outside of the facility.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Narrative:  Leg pain, ER visit
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for coronary arteriosclerosis, cardiac pacemaker, prostate cancer, hyperlipidemia, htn, ckd stage 3. No cause of death or recent hospitalization, illness docuemented. Deceased 4/21/21 per wife.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Anticoagulant therapy, Asthenia, Benign prostatic hyperplasia, CSF protein increased, CSF test abnormal
Clinical narrative: Narrative: The patient's first Moderna Covid-19 vaccine was on 3/3/21, and the second dose was on 3/31/21. The 74 year old patient was admitted to the hospital on 4/24/21 secondary to significant weakness causing the patient inability to walk or stand on his own. He had been seen 2 days prior to the hospital admission in the ER for right-sided weakness. At that time, a stroke workup was done, and the patient was discharged. Since then the patient had progressive worsening of the weakness with lower motor neuron symptoms, and became unable to swallow and non-verbal. A spinal fluid analysis showed elevated protein, and expected to have Guillian-Barre (Miller Fisher variant). The patient completed 5 days of Privigen with immediate and significant improvement in symptoms. The patient had an NGT placed and was intubated from 4/26-4/29 secondary to respiratory distress; on a ventilator. During the course of the hospital stay, the patient experienced BPH with urinary retention, a swollen left upper extremity (no DVT on ultrasound), labile blood pressure (started on lisinopril 2.5mg daily but dc'd due to hypotension, also hypotension with hydralazine), lung infiltrates, and DVT prophylaxis (Lovenox, subq heparin.) Once stabilized, the patient was transferred to Inpatient Rehab, where he remained for over 2 weeks.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest X-ray, Dysphagia, Dysstasia, Endotracheal intubation, Gait disturbance
Clinical narrative: Narrative: The patient's first Moderna Covid-19 vaccine was on 3/3/21, and the second dose was on 3/31/21. The 74 year old patient was admitted to the hospital on 4/24/21 secondary to significant weakness causing the patient inability to walk or stand on his own. He had been seen 2 days prior to the hospital admission in the ER for right-sided weakness. At that time, a stroke workup was done, and the patient was discharged. Since then the patient had progressive worsening of the weakness with lower motor neuron symptoms, and became unable to swallow and non-verbal. A spinal fluid analysis showed elevated protein, and expected to have Guillian-Barre (Miller Fisher variant). The patient completed 5 days of Privigen with immediate and significant improvement in symptoms. The patient had an NGT placed and was intubated from 4/26-4/29 secondary to respiratory distress; on a ventilator. During the course of the hospital stay, the patient experienced BPH with urinary retention, a swollen left upper extremity (no DVT on ultrasound), labile blood pressure (started on lisinopril 2.5mg daily but dc'd due to hypotension, also hypotension with hydralazine), lung infiltrates, and DVT prophylaxis (Lovenox, subq heparin.) Once stabilized, the patient was transferred to Inpatient Rehab, where he remained for over 2 weeks.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Gastrointestinal tube insertion, Guillain-Barre syndrome, Hemiparesis, Injection site swelling, Labile blood pressure
Clinical narrative: Narrative: The patient's first Moderna Covid-19 vaccine was on 3/3/21, and the second dose was on 3/31/21. The 74 year old patient was admitted to the hospital on 4/24/21 secondary to significant weakness causing the patient inability to walk or stand on his own. He had been seen 2 days prior to the hospital admission in the ER for right-sided weakness. At that time, a stroke workup was done, and the patient was discharged. Since then the patient had progressive worsening of the weakness with lower motor neuron symptoms, and became unable to swallow and non-verbal. A spinal fluid analysis showed elevated protein, and expected to have Guillian-Barre (Miller Fisher variant). The patient completed 5 days of Privigen with immediate and significant improvement in symptoms. The patient had an NGT placed and was intubated from 4/26-4/29 secondary to respiratory distress; on a ventilator. During the course of the hospital stay, the patient experienced BPH with urinary retention, a swollen left upper extremity (no DVT on ultrasound), labile blood pressure (started on lisinopril 2.5mg daily but dc'd due to hypotension, also hypotension with hydralazine), lung infiltrates, and DVT prophylaxis (Lovenox, subq heparin.) Once stabilized, the patient was transferred to Inpatient Rehab, where he remained for over 2 weeks.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lumbar puncture, Lung infiltration, Magnetic resonance imaging spinal, Mechanical ventilation, Miller Fisher syndrome
Clinical narrative: Narrative: The patient's first Moderna Covid-19 vaccine was on 3/3/21, and the second dose was on 3/31/21. The 74 year old patient was admitted to the hospital on 4/24/21 secondary to significant weakness causing the patient inability to walk or stand on his own. He had been seen 2 days prior to the hospital admission in the ER for right-sided weakness. At that time, a stroke workup was done, and the patient was discharged. Since then the patient had progressive worsening of the weakness with lower motor neuron symptoms, and became unable to swallow and non-verbal. A spinal fluid analysis showed elevated protein, and expected to have Guillian-Barre (Miller Fisher variant). The patient completed 5 days of Privigen with immediate and significant improvement in symptoms. The patient had an NGT placed and was intubated from 4/26-4/29 secondary to respiratory distress; on a ventilator. During the course of the hospital stay, the patient experienced BPH with urinary retention, a swollen left upper extremity (no DVT on ultrasound), labile blood pressure (started on lisinopril 2.5mg daily but dc'd due to hypotension, also hypotension with hydralazine), lung infiltrates, and DVT prophylaxis (Lovenox, subq heparin.) Once stabilized, the patient was transferred to Inpatient Rehab, where he remained for over 2 weeks.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Motor neurone disease, Respiratory distress, Speech disorder, Ultrasound Doppler normal, Urinary retention
Clinical narrative: Narrative: The patient's first Moderna Covid-19 vaccine was on 3/3/21, and the second dose was on 3/31/21. The 74 year old patient was admitted to the hospital on 4/24/21 secondary to significant weakness causing the patient inability to walk or stand on his own. He had been seen 2 days prior to the hospital admission in the ER for right-sided weakness. At that time, a stroke workup was done, and the patient was discharged. Since then the patient had progressive worsening of the weakness with lower motor neuron symptoms, and became unable to swallow and non-verbal. A spinal fluid analysis showed elevated protein, and expected to have Guillian-Barre (Miller Fisher variant). The patient completed 5 days of Privigen with immediate and significant improvement in symptoms. The patient had an NGT placed and was intubated from 4/26-4/29 secondary to respiratory distress; on a ventilator. During the course of the hospital stay, the patient experienced BPH with urinary retention, a swollen left upper extremity (no DVT on ultrasound), labile blood pressure (started on lisinopril 2.5mg daily but dc'd due to hypotension, also hypotension with hydralazine), lung infiltrates, and DVT prophylaxis (Lovenox, subq heparin.) Once stabilized, the patient was transferred to Inpatient Rehab, where he remained for over 2 weeks.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: Narrative:  60 yo male patient who was already hospitalized for another medical issues received the COVID vaccine (first dose). He developed dyspnea, was monitored, and symptoms resolved. Was given dose 2 of the series without issue.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Blister, Urticaria, Vaccination site urticaria, Vaccination site vesicles
Clinical narrative: Narrative: Hives/blisters after second dose of Pfizer. These developed 1 week after the second dose. Per pt it started at the site of vaccination and then extended to entire body including scalp, perineum, torso. There was blistering. He went to local ED. He received Pfizer vaccine at Pharmacy where he is pharmacy tech Pt went to local ED and was given PO steroids, steroids topical. Specific dates of vaccination, date of reaction, and treatment medication name/dose unknown.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death
Clinical narrative: Narrative:  Patient did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient past medical history include Obstructive sleep apnea of adults, Long term current use of anticoagulation, Transplanted liver present, Coronary Arteriosclerosis, Sleep Apnea, Hearing loss, COPD, A.Fib, Benign Prostate Hyperplasia. Patient had completed two series of covid vaccine back in Jan-Feb 2021. Recently patient was admitted to local ER on May 6th with covid diagnosis. Patient was transferred to Inpatient hospice on 5.15 and expired on 5.16 per very limited records received for hospital. No other detailed notes were found.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: Narrative:  Covid vaccine doses #1 and #2 were given 20 days apart instead of 28 days +/- 4 per manufacturer/CDC recommendations. Dose #1 given 2/21/2021, Dose #2 3/11/2021. Pt reported no side effects from either dose of vaccine.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Mobility decreased
Clinical narrative: Narrative: Went to ER with chills, and terrible HA. Described as worst HA ever and feeling like skull was being cracked. HA lasted for 9 days, during that time she was unable to get out of bed - treated with percocet 10/325mg prn with minimal relief (rx'ed from hospital). After the 9 days, she has still been having intermittent HAs - but not to the severity of the initial one. Neurologist is aware (patient has h/o migraines).
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Condition aggravated, Death, Failure to thrive, Malnutrition
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.)  for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for tubal ligation, gastric bypass, ESLD, IDA. Admitted in February from 1st to 19th with generalized weakness related to protein calories malnutrition. hgb was 4.3 on presentation. Admitted 4/15 with CC of weakness, failure to thrive, severe protein calories malnutrition. Was also under the care of palliative medicine. Discharged 5/4. Transported to outside entity care center 5/17. deceased 5/18. no cause of death available.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Activated partial thromboplastin time, Alanine aminotransferase, Anti-platelet factor 4 antibody positive, Aspartate aminotransferase
Clinical narrative: Narrative:  Pt presented to the ED on 5/12/21 with abdominal pain, nausea, and vomiting x 3 days (similar to previous episodes); work-up was negative and patient was discharged home. On 5/14/21 pt brought to ED for AMS, after EMS found her hypoglycemic at home after presumed seizure. Neurology was consulted and patient was started on Keppra daily for which she has not had any recurrent episodes of seizures. During this admission, she was also found to have acute reduced in EF on TTE (45%  to 15% in 3 months). Course of admission was c/b transaminitis. GI was consulted who thought that this could be due to ischemic liver injury 2/2 to heart failure. LFTs improved significantly with GDMT. On admission, labs were consistent with DIC with thrombocytopenia. No evidence of  thrombosis (other than on the false lumen of previously repaired aortic aneurysm), no evidence of bleeding. Patient found to have acute thrombocytopenia and DIC. Per consistent with DIC unclear and likely multifactorial. Etiology of thrombocytopenia and DIC may be from vaccine given heparin-PF4 antibody was positive. Patient was started on high dose steroids 5/16/21 for possible autoimmune thrombocytopenia with subsequent taper with improvement.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Disseminated intravascular coagulation, Echocardiogram abnormal, Ejection fraction decreased, Haemoglobin, Hypertransaminasaemia
Clinical narrative: Narrative:  Pt presented to the ED on 5/12/21 with abdominal pain, nausea, and vomiting x 3 days (similar to previous episodes); work-up was negative and patient was discharged home. On 5/14/21 pt brought to ED for AMS, after EMS found her hypoglycemic at home after presumed seizure. Neurology was consulted and patient was started on Keppra daily for which she has not had any recurrent episodes of seizures. During this admission, she was also found to have acute reduced in EF on TTE (45%  to 15% in 3 months). Course of admission was c/b transaminitis. GI was consulted who thought that this could be due to ischemic liver injury 2/2 to heart failure. LFTs improved significantly with GDMT. On admission, labs were consistent with DIC with thrombocytopenia. No evidence of  thrombosis (other than on the false lumen of previously repaired aortic aneurysm), no evidence of bleeding. Patient found to have acute thrombocytopenia and DIC. Per consistent with DIC unclear and likely multifactorial. Etiology of thrombocytopenia and DIC may be from vaccine given heparin-PF4 antibody was positive. Patient was started on high dose steroids 5/16/21 for possible autoimmune thrombocytopenia with subsequent taper with improvement.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoglycaemia, International normalised ratio, Laboratory test abnormal, Liver function test abnormal, Mental status changes
Clinical narrative: Narrative:  Pt presented to the ED on 5/12/21 with abdominal pain, nausea, and vomiting x 3 days (similar to previous episodes); work-up was negative and patient was discharged home. On 5/14/21 pt brought to ED for AMS, after EMS found her hypoglycemic at home after presumed seizure. Neurology was consulted and patient was started on Keppra daily for which she has not had any recurrent episodes of seizures. During this admission, she was also found to have acute reduced in EF on TTE (45%  to 15% in 3 months). Course of admission was c/b transaminitis. GI was consulted who thought that this could be due to ischemic liver injury 2/2 to heart failure. LFTs improved significantly with GDMT. On admission, labs were consistent with DIC with thrombocytopenia. No evidence of  thrombosis (other than on the false lumen of previously repaired aortic aneurysm), no evidence of bleeding. Patient found to have acute thrombocytopenia and DIC. Per consistent with DIC unclear and likely multifactorial. Etiology of thrombocytopenia and DIC may be from vaccine given heparin-PF4 antibody was positive. Patient was started on high dose steroids 5/16/21 for possible autoimmune thrombocytopenia with subsequent taper with improvement.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Platelet count, Seizure, Thrombocytopenia, Vomiting
Clinical narrative: Narrative:  Pt presented to the ED on 5/12/21 with abdominal pain, nausea, and vomiting x 3 days (similar to previous episodes); work-up was negative and patient was discharged home. On 5/14/21 pt brought to ED for AMS, after EMS found her hypoglycemic at home after presumed seizure. Neurology was consulted and patient was started on Keppra daily for which she has not had any recurrent episodes of seizures. During this admission, she was also found to have acute reduced in EF on TTE (45%  to 15% in 3 months). Course of admission was c/b transaminitis. GI was consulted who thought that this could be due to ischemic liver injury 2/2 to heart failure. LFTs improved significantly with GDMT. On admission, labs were consistent with DIC with thrombocytopenia. No evidence of  thrombosis (other than on the false lumen of previously repaired aortic aneurysm), no evidence of bleeding. Patient found to have acute thrombocytopenia and DIC. Per consistent with DIC unclear and likely multifactorial. Etiology of thrombocytopenia and DIC may be from vaccine given heparin-PF4 antibody was positive. Patient was started on high dose steroids 5/16/21 for possible autoimmune thrombocytopenia with subsequent taper with improvement.
Age: 92.0
Sex: M
Vaccine: COVID19
Symptoms: General physical health deterioration, Mobility decreased
Clinical narrative: Narrative:  Pt was a 91 YO male with PMH of vasculer dementia, HTN, HDL, SSS s/p pacer, and urinary incontinence referred to hospice for dementia; pt ultimately refused hospice care. Pt's family feels that his decline accelerated after receiving 2nd COVID vaccine. This assertion was not corroborated by provider in chart. Pt's family also stated their belief that his refusal to leave bed was symptomatic of depression & grief.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Unevaluable event
Clinical narrative: Narrative:
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Hypersensitivity, Pruritus, Tongue disorder
Clinical narrative: Narrative:  The patient is a 49yo female hx asthma, anaphylaxis, multiple food allergies, and seasonal allergies presenting with complaint of allergic reaction following COVID-19 vaccination. Patient was vaccinated at approximately 1020 and states that she has had symptoms since approximately 1050. She reports pruritus that has spread from his face down to her legs, including her back. She also complains of shortness of breath. She states that her "tongue feels thicker toward the back." She was cared for in the ED and then released home on the same day.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Death
Clinical narrative: Narrative: Patient received Moderna Covid vaccine #1 on 3/23/21 and #2 on 4/20/21. No notes in system or scanned records to indicate what happened from the time of second vaccine to recorded date of death of 5/16/21. He did however no show two primary care appointments between his first and second vaccine. There were 26 days from time of second vaccine to date of death. No autopsy report available.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Muscular weakness
Clinical narrative: Narrative: 48 yo female patient states felt dizziness,fatique,bilateral leg weakness after vaccination Monitored at the facility and symptoms resolved.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Narrative: Patient reported itching shortly after vaccine administration. Received cetirizine and was discharged at 1:20p stating she felt better and the itching was decreased. The patient has her own epi-pen for her pre-existing allergies if needed after discharge.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, Computerised tomogram abdomen, Computerised tomogram thorax abnormal, Pulmonary embolism
Clinical narrative: Narrative:  Patient had a PCP visit on 04/02/2021. Found to have unintentional weight loss and agreed to having a CT of chest/abdomen/pelvis with contrast. On 4/02/2021 he received the Janssen COVID-19 vaccine. Patient's CT was scheduled for 04/24/2021, where it was found he had an incidental finding of a pulmonary embolism. He was started on apixaban at that time.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Hypotension, SARS-CoV-2 test positive
Clinical narrative: Narrative:  A 53yo B. male with PMH of GERD, Chronic Back Pain, Urticaria, HTN, ED, DMII, Hyperlipidemia, Tobacco use, Cerebral Infraction, Dysphagia,  Slurred Speech and Aphasia Received his Pfizer's Covid -19 vaccine first dose on  March 6, 2021at 08:45AM and second dose on March 26, 2021 at 09:00AM He was presented to the ED on March 11, 2021 with weakness and Hypotension and was reported Covid-19+vve
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  68 y.o. male patient who received dose #1 of the Moderna COVID vaccine (Lot #029L20A, exp 7/13/21) on 1/29/21 and dose #2 of the Moderna COVID vaccine (Lot #011A21A exp 8/16/21) on 3/1/21. Patient had multiple comorbidities including: CHF, HTN, chest pain, dementia, COPD, Tobacco use, hypothyroidism, and alcohol use disorder. Patient was admitted to the hospital on 1/10/21 for respiratory failure/CHF exacerbation. He was then transferred to CLC 01/28/2021, hospital 01/31/2021 - 02/02/2021 (ASC rule out), then transitioned to inpatient hospice after discharge from hospital. Patient had an acute decline during hospital and passed in the CLC on 3/10/2021 @ 12:17. Reaction classified as severe as death occurred following vaccination.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, SARS-CoV-2 antibody test, SARS-CoV-2 antibody test positive, SARS-CoV-2 test positive
Clinical narrative: Narrative:  pt got COVID-19 pna 2+ months after receiving 2 doses of Moderna COVID-19 Vaccine, pt also w/ (+) COVID-19 Abx test before during and after COVID-19 infxn.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Asthenia, COVID-19, Chills, Cough
Clinical narrative: Narrative:  66-year-old female presented to EDfor evaluation of cough, shortness of breath, weakness, fever, chills, not feeling well. She received her COVID-19 to her knowledge. Her COVID-19 test was positive at ED. She felt markedly improved after liter of IV fluids, IV Solu-Medrol, and observation. Her oxygen saturations were in the 97% range. Pt was discharged the same day. Of note,  patient had anxiety and headache with the first dose of covid-19 vaccine, no adverse events were reported with second dose.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Headache, Malaise, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Narrative:  66-year-old female presented to EDfor evaluation of cough, shortness of breath, weakness, fever, chills, not feeling well. She received her COVID-19 to her knowledge. Her COVID-19 test was positive at ED. She felt markedly improved after liter of IV fluids, IV Solu-Medrol, and observation. Her oxygen saturations were in the 97% range. Pt was discharged the same day. Of note,  patient had anxiety and headache with the first dose of covid-19 vaccine, no adverse events were reported with second dose.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Narrative: 51 yo female patient who developed a rash after receiving her first dose of the COVID vaccine. Her symptoms resolved after time and diphenhydramine. She received her 2nd vaccine without incident.